There were 285 consecutive cervical and lumbar fusion patients who underwent the procedure and were included in the study. The bone grafts were processed from 114 donors of various ages. Here are five quick facts about the study:
• There was a 98 percent fusion rate at 12 months
• No correlation between fusion rate and allograft donor age was shown
• The product’s age did not have an impact on fusion rate
• Whether the product was terminally sterilized with a low dose gamma irradiation did not make an impact on the fusion rate
• OsteoAMP could be a lower-cost alternative to recombinant growth factors
The fusion rates were evaluated through a blinded radiological fusion assessment. OsteoAMP comes in granules, compressible sponges, putty and structural grafts for different surgeon options based on patient needs.
Advanced Biologics is a privately-held company focused on developing biologic solutions across medical specialties.
More articles on orthopedic devices:
Ronda Stryker sells 21k shares in August so far: 5 things to know
21 spine devices receive FDA 510(k) clearances in July
8 spinal implant market trends through 2022
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
